Kawasaki disease in Jordan: demographics, presentation, and outcome

Cardiol Young. 2012 Aug;22(4):390-5. doi: 10.1017/S1047951111001818. Epub 2011 Nov 9.

Abstract

Kawasaki disease is the leading cause of acquired coronary artery disease in young children. There is a lack of data on Kawasaki disease and its effect on coronary arteries in Jordan and other developing countries. We report clinical and demographic data of Kawasaki disease in Jordan from a single institution, with emphasis on cardiac involvement and short to intermediate follow-up. Review of the medical records of 34 patients with Kawasaki disease from 1997 to 2010 was done for clinical and demographic variables. Echocardiographic and angiographic images were reviewed for patients at presentation and follow-up. The median age at presentation was 19 months, ranging from 2 months to 8 years, with a male to female ratio of 3.9:1. In all, 12 patients (35%) had incomplete Kawasaki disease. There was a high incidence of coronary artery involvement (41%), where 20.5% had aneurysms and 20.5% had ectasia without aneurysm. Most coronary aneurysms were present at the time of diagnosis. The only independent variable for prediction of coronary involvement was age, with an odds ratio of 0.63 per year (95% confidence interval 0.41-0.95).

MeSH terms

  • Age Factors
  • Child
  • Child, Preschool
  • Coronary Aneurysm / diagnostic imaging
  • Coronary Aneurysm / epidemiology
  • Coronary Aneurysm / etiology*
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / epidemiology
  • Coronary Artery Disease / etiology*
  • Coronary Vessels / diagnostic imaging
  • Dilatation, Pathologic
  • Echocardiography
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Infant
  • Jordan / epidemiology
  • Logistic Models
  • Male
  • Mucocutaneous Lymph Node Syndrome* / complications
  • Mucocutaneous Lymph Node Syndrome* / drug therapy
  • Mucocutaneous Lymph Node Syndrome* / epidemiology
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors